Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...
Roth Capital Partners launched coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and $9 price target. The stock closed at $1.59 on April 13. Stealth is focused on developing drugs targeted for rare...
Roth Capital Partners launched coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $44 price target. The stock closed at $5.74 on March 24. Immunic is focused on developing innovative new modulators of the immune...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431, a cyclophilin inhibitor with antifibrotic and antiviral properties, may show some effect in the ongoing COVID-19 pandemic, according to Roth Capital Partners and Brookline...
Roth Capital Partners believes Allena Pharmaceuticals (NASDAQ:ALNA) is getting “unnecessarily punished” on Nov. 7, despite positive URIROX-1 top-line study data, which included a high placebo response, smaller treatment...
Roth Capital Partners doubled its price target for Juniper Pharmaceuticals (NASDAQ:JNP) to $24 from $12 after the company reported 2017 results. The stock closed at $10 on March 9. Juniper is focused on developing...